Sugi Predict

Sugi Predict / Compounds / SCHEMBL299879

SCHEMBL299879

SCHEMBL299879

O=C(Nc1ccccc1)c1cccc([N+](=O)[O-])c1

nearest known ligand 0.88

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 10/20 0.88
▸ MEN1 O00255 9/20 0.88
▸ MAPT P10636 5/20 0.80
▸ POLB P06746 2/20 0.80
▸ BLM P54132 1/20 0.80
▸ ALOX5 P09917 2/20 0.77
▸ THRA P10827 1/20 0.74
▸ NPC1 O15118 3/20 0.72
▸ RAB9A P51151 3/20 0.72
▸ ALDH1A1 P00352 3/20 0.72
▸ MITF O75030 1/20 0.69
▸ CYP1A2 P05177 1/20 0.69
▸ CYP3A4 P08684 1/20 0.69
▸ CYP2C9 P11712 1/20 0.69
▸ LMNA P02545 1/20 0.69
▸ FFAR1 O14842 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30868371 1.00 KMT2A (0.88) KMT2AMEN1MAPTPOLBBLM
SCHEMBL10943066 0.92 KMT2A (0.94) KMT2AMEN1MAPTPOLBBLM
SCHEMBL6795867 0.91 MEN1 (0.85) KMT2AMEN1MAPTPOLBBLM
SCHEMBL1028236 0.90 KMT2A (0.78) KMT2AMEN1MAPTPOLBBLM
SCHEMBL1028237 0.90 KMT2A (0.78) KMT2AMEN1MAPTPOLBBLM
Iodide SCHEMBL30758621 0.89 MEN1 (0.83) KMT2AMEN1MAPTPOLBBLM
SCHEMBL32690121 0.89 MEN1 (1.00) KMT2AMEN1MAPTPOLBBLM
SCHEMBL18300094 0.89 MEN1 (1.00) KMT2AMEN1MAPTPOLBBLM
Hydrochloric Acid SCHEMBL2106899 0.88 MEN1 (0.76) KMT2AMEN1MAPTPOLBBLM
SCHEMBL94830 0.88 KMT2A (0.88) KMT2AMEN1MAPTPOLBBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4663636-A2 TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BioCryst Pharmaceuticals, Inc. (US) 2025-12-17 — — EP disclosed
US-20250270171-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-08-28 — — US disclosed
US-20250257040-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-08-14 — — US disclosed
EP-4180424-B1 SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BIOCRYST PHARM INC (US) 2025-06-25 — — EP disclosed
CN-120000651-A Application of beta-carboline compounds in preparation of medicines for preventing and/or treating acute lung injury 中国人民解放军北部战区总医院 2025-05-16 — — CN disclosed
CN-119899184-A Beta-carboline compound, preparation method thereof and application thereof in resisting Alzheimer disease 中国人民解放军北部战区总医院 2025-04-29 — — CN disclosed
US-12162838-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2024-12-10 — — US disclosed
US-12116346-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2024-10-15 — — US disclosed
CN-113307772-B Human plasma kallikrein inhibitors 拜奥克里斯特制药公司 2024-06-28 — — CN disclosed
US-20240150296-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-05-09 — — US disclosed
US-20030004162-A1 Use of glycogen phosphorylase inhibitors TREADWAY JUDITH L (US) 2003-01-02 — — US disclosed
US-20020031816-A1 METHOD OF INHIBITION OF HUMAN GLYCOGEN PHOSPHORYLASE PFIZER PRODUCTS INC. 2002-03-14 — — US disclosed
EP-1136071-A2 Use of glycogen phosphorylase inhibitors Pfizer Products Inc. (US) 2001-09-26 — — EP disclosed
EP-0978279-A1 Inhibitors of human glycogen phosphorylase Pfizer Products Inc. (US) 2000-02-09 — — EP disclosed
US-5998463-A Glycogen phosphorylase inhibitors PFIZER INC (US) 1999-12-07 — — US disclosed
US-5728835-A HYPOTENSIVE AGENTS; ANTIISCHEMIC AGENTS TOA EIYO, LTD. (JP) 1998-03-17 — — US disclosed
EP-0661266-A1 Substituted cyclic amine compounds as 5HT2 antagonists TOA EIYO LTD. (JP) 1995-07-05 — — EP disclosed
US-4499167-A Photoconductive compositions comprising an organic photoconductor and an amide compound and electro-photographic light-sensitive materials using the compositions FUJI PHOTO FILM CO., LTD. (JP) 1985-02-12 — — US disclosed
US-4282369-A HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1981-08-04 — — US disclosed
US-4227007-A HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1980-10-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12116346-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 KMT2A 1644/4885MEN1 407/4885MAPT 2984/4885
US-20250270171-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 KMT2A 1644/4885MEN1 407/4885MAPT 2984/4885
US-20240150296-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 KMT2A 1644/4885MEN1 407/4885MAPT 2984/4885
US-20250257040-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 KMT2A 1644/4885MEN1 407/4885MAPT 2984/4885
US-20030004162-A1 Use of glycogen phosphorylase inhibitors PYGL, PYGM, GYS2 KMT2A 2831/4885MEN1 4180/4885MAPT 3518/4885
US-12162838-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 KMT2A 1644/4885MEN1 407/4885MAPT 2984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.